Information Provided By: 
Fly News Breaks for June 19, 2017
CLVS, TSRO
Jun 19, 2017 | 10:13 EDT
Jefferies analyst Eun Yang views Clovis Oncology's (CLVS) data today for rucaparib as "highly competitive" to Tesaro's (TSRO) niraparib. The data from Clovis will likely impact any potential takeover premium for Tesaro, Yang tells investors in a research note. The analyst views Tesaro as being worth $80 per share on a fundamental basis. She has a Hold rating and $124 price target on the shares. Tesaro in early trading is down 5%, or $7.09, to $137.22.
News For TSRO;CLVS From the Last 2 Days
There are no results for your query TSRO;CLVS
